Mirion Technologies, Inc. (MIR)
| Market Cap | 4.60B +37.1% |
| Revenue (ttm) | 981.00M +12.7% |
| Net Income | 25.10M |
| EPS | 0.10 |
| Shares Out | 250.42M |
| PE Ratio | 184.32 |
| Forward PE | 32.60 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,442,481 |
| Open | 17.85 |
| Previous Close | 18.03 |
| Day's Range | 17.59 - 18.27 |
| 52-Week Range | 16.43 - 30.28 |
| Beta | 1.07 |
| Analysts | Strong Buy |
| Price Target | 27.90 (+51.88%) |
| Earnings Date | Apr 28, 2026 |
About MIR
Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in North America, Europe, and the Asia Pacific. It operates in two segments, Medical, and Nuclear & Safety. The Medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medi... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for MIR stock is "Strong Buy." The 12-month stock price target is $27.9, which is an increase of 51.88% from the latest price.
News
Mirion Technologies Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals approved. No questions were raised during the Q&A, and risks related to forward-looking statements were noted.
Partnerships, Positive Sentiment Boost U.S. Nuclear
The nuclear industry has seen a recent flurry of announcements, headlined by two major industry partnerships to rapidly deploy new reactors. These exciting developments come against the backdrop of a ...
Mirion price target lowered to $28 from $29 at Evercore ISI
Evercore ISI lowered the firm’s price target on Mirion (MIR) to $28 from $29 and keeps an Outperform rating on the shares.
Mirion price target lowered to $28 from $29 at Citi
Citi lowered the firm’s price target on Mirion (MIR) to $28 from $29 and keeps a Buy rating on the shares.
Mirion Technologies Earnings Call Transcript: Q1 2026
Orders and backlog surged on strong nuclear and medical segment growth, with Paragon and Certrec acquisitions driving early synergies. Revenue and adjusted EBITDA rose year-over-year, and guidance remains confident for 2026, with margin expansion and robust nuclear demand expected.
Mirion Technologies Earnings release: Q1 2026
Mirion Technologies released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Mirion Technologies Slides: Q1 2026
Mirion Technologies has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
Mirion Technologies Quarterly report: Q1 2026
Mirion Technologies has published its Q1 2026 quarterly earnings report on April 29, 2026.
Mirion reports Q1 adjusted EPS 10c, consensus 9c
Reports Q1 revenue $257.6M, consensus $244.77M. “Our first quarter performance showcased substantial orders growth led by nuclear power demand and as-expected Adjusted EBITDA performance and margins,”...
Mirion Announces First Quarter 2026 Financial Results
ATLANTA--(BUSINESS WIRE)--Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and re...
Mirion Announces Earnings Release and Conference Call Date for First Quarter 2026
ATLANTA--(BUSINESS WIRE)--Mirion (NYSE: MIR) announced today that it will release financial results for first quarter 2026 after market close on Tuesday, April 28, 2026. Following the news release, th...
Mirion price target lowered to $28 from $29 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Mirion (MIR) to $28 from $29 and keeps a Buy rating on the shares as part of a broader research note previewing…
Mirion Technologies Proxy statement: Proxy filing
Mirion Technologies filed a proxy statement on April 1, 2026, providing details for shareholder voting and corporate governance matters.
Mirion Technologies Proxy statement: Proxy filing
Mirion Technologies filed a proxy statement on April 1, 2026, providing details for shareholder voting and corporate governance matters.
Mirion price target lowered to $26 from $29 at Baird
Baird analyst Quinn Fredrickson lowered the firm’s price target on Mirion (MIR) to $26 from $29 and keeps an Outperform rating on the shares. The firm remains positive on the…
Mirion price target lowered to $27 from $30 at JPMorgan
JPMorgan lowered the firm’s price target on Mirion (MIR) to $27 from $30 and keeps an Overweight rating on the shares. The firm updated models in the North American small-cap…
Mirion price target lowered to $27 from $29 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Mirion (MIR) to $27 from $29 and keeps an Equal Weight rating on the shares. The firm is updating and rolling forward…
Mirion price target lowered to $30 from $33 at JPMorgan
JPMorgan analyst Tomohiko Sano lowered the firm’s price target on Mirion (MIR) to $30 from $33 and keeps an Overweight rating on the shares. The firm says that as macro…
Mirion Technologies Transcript: Citi's Global Industrial Tech & Mobility Conference 2026
Nuclear power drives nearly half of revenue, with strong growth in SMRs, international projects, and recurring installed base business. Margin expansion, robust backlog, and AI-driven productivity are key themes, while medical and nuclear medicine segments show continued growth potential.
Mirion price target lowered to $29 from $30 at Baird
Baird lowered the firm’s price target on Mirion (MIR) to $29 from $30 and keeps an Outperform rating on the shares. The firm updated its model following mixed Q4 results…
Mirion to Present at Citi's 2026 Global Industrial Tech and Mobility Conference
ATLANTA--(BUSINESS WIRE)--Mirion (NYSE: MIR) announced today that Chairman and Chief Executive Officer, Thomas Logan, and Chief Financial Officer and Medical Group President, Brian Schopfer, will pres...
Mirion price target lowered to $29 from $33 at Goldman Sachs, says buy the dip
Goldman Sachs lowered the firm’s price target on Mirion (MIR) to $29 from $33 and keeps a Buy rating on the shares. Mirion posted Q4 adjusted EBITDA of $77.6M, driven…
Mirion price target lowered to $29 from $32 at Citi
Citi lowered the firm’s price target on Mirion (MIR) to $29 from $32 and keeps a Buy rating on the shares.
Mirion Technologies Earnings Call Transcript: Q4 2025
Record orders and strong growth in nuclear power and medicine drove 2025 results, with revenue up 7.5% and Adjusted EBITDA up 12%. 2026 guidance calls for 22%-24% revenue growth, margin expansion, and robust free cash flow, supported by recent acquisitions and a growing project pipeline.
Mirion Technologies Annual report: Q4 2025
Mirion Technologies has published its Q4 2025 annual report on February 11, 2026.